Market closedNon-fractional

Novavax/NVAX

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX

About Novavax

Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. Novavax works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The Company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from Europe.

Ticker

NVAX

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology

Headquarters

Gaithersburg, United States

Employees

1,543

Novavax Metrics

BasicAdvanced
$1.9B
Market cap
-
P/E ratio
-$3.49
EPS
1.62
Beta
-
Dividend rate
$1.9B
1.62
0.904
0.624
-66.287
-67.012
-26.61%
-16.32%
45.24%
1.587
-2.25
-1.97
-3.075
-26.66%
-75.71%
2.72%
-28.39%

What the Analysts think about Novavax

Analyst Ratings

Majority rating from 6 analysts.
Buy

Novavax Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-157.24% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$94M
-67.80%
Net income
-$148M
-17.27%
Profit margin
-157.24%
156.93%

Novavax Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 1.32%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
$0.58
-$1.26
-$1.44
-$1.05
-
Expected
-$1.39
-$1.83
-$0.45
-$1.06
$1.36
Surprise
-141.83%
-31.21%
221.19%
-1.32%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Novavax stock?

Novavax (NVAX) has a market cap of $1.9B as of July 23, 2024.

What is the P/E ratio for Novavax stock?

The price to earnings (P/E) ratio for Novavax (NVAX) stock is 0 as of July 23, 2024.

Does Novavax stock pay dividends?

No, Novavax (NVAX) stock does not pay dividends to its shareholders as of July 23, 2024.

When is the next Novavax dividend payment date?

Novavax (NVAX) stock does not pay dividends to its shareholders.

What is the beta indicator for Novavax?

Novavax (NVAX) has a beta rating of 1.62. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

Buy or sell Novavax stock

Buy or sell Novavax stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing